Article
FOXA1 in prostate cancer.
Asian journal of andrology - 1 Jan 2000
Dong Hui-Yu, Ding Lei, Zhou Tian-Ren, Yan Tao, Li Jie, Liang Chao
Abstract excerpt
Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional network shifted. Forkhead box protein A1 (FOXA1) may play a key role in this process through multiple mechanisms. To...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
